Molecular Signature Pregnancy (MSP)

• ClinicalTrials.gov Identifier: NCT02797327
• Recruitment Status: Unknown
• First Posted: June 13, 2016
• Last Update Posted: September 2, 2020
• Sponsor: University of Oxford
• Collaborator: Sidra Medical and Research Center
• Information provided by (Responsible Party): University of Oxford

Study Description

Brief Summary:

The primary goal of the study is to identify biomarkers from the molecular signature predictive of pre-term birth. This will be achieved through high frequency sampling and profiling throughout pregnancy.

Condition or disease
Pregnancy

Detailed Description:

BACKGROUND Preterm birth occurs before 37 weeks and is a major cause of neonatal mortality and morbidity, and affecting 8% of newborns on the Thailand-Myanmar border. Identifying biochemical markers that are associated with preterm birth can guide in designing the most effective targeted intervention strategies for women at risk.

In order to identify biomarkers signatures predictive of preterm birth the investigators will employ high throughput profiling technologies (aka "a systems approach") that maximize the amount of information that can be obtained and knowledge generated from each participant sample. Preliminary data will also be obtained for infectious complications in order to assess potential for a systems approach such approach in detecting infectious events before onset of clinical symptoms or in absence of clinical symptoms. The rationale behind such approach and its importance for establishing personalized medicine approaches was detailed in a recent opinion article published by Dr Chaussabel et al (2015) A vision and a prescription for big data-enabled medicine. Nat Immunol 16: 435-439. In addition parallel studies will be carried out in other countries such as Qatar and the US in order to assess environmental influences on blood and transcriptome signatures.

RESEARCH DESIGN This is a prospective pregnancy cohort from the first trimester until post-partum. The investigators are unable to predict which women will have preterm birth or infection.

STUDY POPULATION 400 Pregnant women with confirmed viable pregnancy of more than 8+0 weeks and less than 14 weeks of pregnancy, who are healthy, intend to deliver at SMRU and can attend for two weekly ANC visits.

METHOD AND TECHNIQUE

• Pregnant women attending SMRU ANC clinics will be invited to participate in the study.

• Study samples will include:

  1. A small blood volume (100 micro litres) will be collected by finger prick sampling via a capillary straw. The sample will be transferred into a microtube containing an RNA stabilizing solution and stored at -80°C. This will be repeated every two weeks, delivery and post-partum.
  2. A stool sample will be collected and stored at -80°C. This will be collected each trimester, delivery and post-partum.
  3. A vaginal swab will be collected from the posterior fornix under direct visualization by the midwife; and stored at -80°C. This will be collected each trimester, delivery and post-partum.

The post-partum visits, will be at 4-6 weeks and at 3months. The investigators estimate 15-18 blood samples, and 6 stool and vaginal swabs will be collected per women if they attend as expected. Fetal growth will be measured by 5-6 weekly ultrasound scans.

The sample set will be repeated if the woman has fever during pregnancy or post-partum (estimated at 5% of the women).

POTENTIAL VALUE Identifying biochemical markers that are associated with preterm can guide in designing the most effective targeted intervention strategies aimed at women at risk for preterm birth.

Study Design

• Study Type: Observational
• Actual Enrollment: 430 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Molecular Signature of Karen and Burmese Pregnant Women on the Thailand-Myanmar Border
• Actual Study Start Date: September 12, 2016
• Estimated Primary Completion Date: February 13, 2021
• Estimated Study Completion Date: February 13, 2021

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :

1. Characterization of the molecular signature of 30 preterm pregnancies defined by real-time PCR [ Time Frame: up to 6 weeks post-partum ]

Secondary Outcome Measures :

1. Proportion of women who completed two weekly sampling [ Time Frame: up to delivery ]
2. Proportion of rate of drop-out from sampling [ Time Frame: up to delivery ]
3. Pain scores of the different samples from pregnant women. [ Time Frame: up to 6 weeks post-partum ]
4. Molecular signature in relation to infection during pregnancy defined by real-time PCR [ Time Frame: up to delivery ]
5. Molecular signature across the duration of pregnancy and post-partum time defined by real-time PCR [ Time Frame: From enrolment at 8-14 weeks of pregnancy to 4-6 weeks post-partum ]

Biospecimen Retention:   Samples With DNA

Blood sample, vaginal swab and stool specimen will be collected.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 49 Years (Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: Yes
• Sampling Method: Non-Probability Sample

Study Population

Target population: First trimester pregnant women with a viable pregnancy who will be followed for the outcome of interest of preterm births on the Thailand-Myanmar border

Criteria

Inclusion Criteria:

• Pregnant woman is willing and able to give informed consent for participation in the study.
• Karen or Burmese, age 18-49 years
• Healthy women with viable singleton first trimester (8+0 to < 14 weeks) pregnancy
• Plan to delivery at SMRU clinic
• Able (in the Investigators opinion) and willing to comply with all study requirements.

Exclusion Criteria:

The participant will not enter the study or continue in the study if ANY of the following apply:

• Emergency obstetric care required
• Pregnant woman (in the investigator's opinion) with medical or obstetrics complications which would make it difficult to comply with study requirements

Contacts and Locations

Locations

Thailand

Shoklo Malaria Research Unit

Mae Sot, Tak, Thailand, 63110

Sponsors and Collaborators

University of Oxford

Sidra Medical and Research Center

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Brummaier T, Syed Ahamed Kabeer B, Wilaisrisak P, Pimanpanarak M, Win AK, Pukrittayakamee S, Marr AK, Kino T, Al Khodor S, Terranegra A, Carrara VI, Nosten F, Utzinger J, Chaussabel D, Paris DH, McGready R. Cohort profile: molecular signature in pregnancy (MSP): longitudinal high-frequency sampling to characterise cross-omic trajectories in pregnancy in a resource-constrained setting. BMJ Open. 2020 Oct 10;10(10):e041631. doi: 10.1136/bmjopen-2020-041631.

Brummaier T, Syed Ahamed Kabeer B, Lindow S, Konje JC, Pukrittayaamee S, Utzinger J, Toufiq M, Antoniou A, Marr AK, Suriyakan S, Kino T, Al Khodor S, Terranegra A, Nosten F, Paris DH, McGready R, Chaussabel D. A prospective cohort for the investigation of alteration in temporal transcriptional and microbiome trajectories preceding preterm birth: a study protocol. BMJ Open. 2019 Jan 15;9(1):e023417. doi: 10.1136/bmjopen-2018-023417.

• Responsible Party: University of Oxford
• ClinicalTrials.gov Identifier: NCT02797327
• Other Study ID Numbers: SMRU1502
• First Posted: June 13, 2016
• Last Update Posted: September 2, 2020
• Last Verified: September 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes

Keywords provided by University of Oxford:

Molecular signature; Thailand-Myanmar border